We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

171 hedge funds and large institutions have $321M invested in PDL BioPharma, Inc. in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 72 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

153% more call options, than puts

Call options by funds: $476K | Put options by funds: $188K

6% more capital invested

Capital invested by funds: $304M → $321M (+$17.6M)

2% less funds holding

Funds holding: 174 → 171 (-3)

13% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 16

47% less repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 72

Holders
171
Holders Change
-3
Holders Change %
-1.72%
% of All Funds
4.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
38
Reduced
72
Closed
16
Calls
$476K
Puts
$188K
Net Calls
+$288K
Net Calls Change
+$252K

Top Buyers

Rank Fund Capital Flow
1
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$4.01M
2
KIM
Kestrel Investment Management
California
+$4M
3
Bank of America
Bank of America
North Carolina
+$3.82M
4
BIP
Brandes Investment Partners
California
+$2.41M
5
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
+$2.31M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$4.16M
2
Morgan Stanley
Morgan Stanley
New York
-$3.23M
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.06M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.01M
5
Mackenzie Financial
Mackenzie Financial
Ontario, Canada
-$2.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
151
Wealthspire Advisors (Maryland)
Maryland
$5K +$3.28K +1,426 +222%
HR
152
Howe & Rusling
New York
$5K +$4.6K +2,000 New
IF
153
Ironwood Financial
Arizona
$3K – – –
CCM
154
Cribstone Capital Management
Maine
$2K – – –
WCBA
155
Weaver C. Barksdale & Associates
Tennessee
$2K – – –
Envestnet Asset Management
156
Envestnet Asset Management
Illinois
$2K +$1.15K +500 +245%
HNB
157
Huntington National Bank
Ohio
$2K +$2.3K +1,000 New
Citigroup
158
Citigroup
New York
$1K -$36.5K -15,850 -96%
DA
159
Denali Advisors
California
$1K – – –
IA
160
IFP Advisors
Florida
$1K – – –
LWCFA
161
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$1K – – –
SPIA
162
Steward Partners Investment Advisory
New York
$1K – – –
US Bancorp
163
US Bancorp
Minnesota
$1K – – –
WA
164
Winfield Associates
Ohio
$1K – – –
SEI Investments
165
SEI Investments
Pennsylvania
$1K +$2 +1 +0.2%
IWM
166
IHT Wealth Management
Illinois
$333 – – –
Thrivent Financial for Lutherans
167
Thrivent Financial for Lutherans
Minnesota
– -$2.2M -969,050 Closed
AC
168
Armistice Capital
New York
– -$1.14M -500,000 Closed
HSBC Holdings
169
HSBC Holdings
United Kingdom
– -$520K -223,634 Closed
Tudor Investment Corp
170
Tudor Investment Corp
Connecticut
– -$484K -213,284 Closed
Arrowstreet Capital
171
Arrowstreet Capital
Massachusetts
– -$298K -131,200 Closed
Balyasny Asset Management
172
Balyasny Asset Management
Illinois
– -$227K -100,017 Closed
Cerity Partners
173
Cerity Partners
New York
– -$163K -71,821 Closed
Grantham, Mayo, Van Otterloo & Co (GMO)
174
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
– -$145K -63,997 Closed
ACI
175
AMP Capital Investors
Australia
– -$89K -41,114 Closed
4 5 6
7
8

PDLI Hedge Fund Activity: Q2 2017 in Review

171 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q2 2017, worth a combined $321M — up 5.8% from $304M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PDLI and 14 opened new positions — a net loss of 2 holders — while 72 trimmed existing stakes and 38 added.

The largest buyer was Dimensional Fund Advisors, adding an estimated $4.01M. The largest seller was Citadel Advisors, cutting an estimated $4.16M.

  • 171 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q2 2017, down from 174 in Q1 2017.
  • Funds reported $321M of PDL BioPharma, Inc. stock for Q2 2017, up 5.8% quarter-over-quarter.
  • 14 funds opened new PDL BioPharma, Inc. positions in Q2 2017 and 16 closed out, a net change of -2 holders.
  • The largest PDL BioPharma, Inc. buyer in Q2 2017 was Dimensional Fund Advisors, an estimated $4.01M added.
  • The largest PDL BioPharma, Inc. seller in Q2 2017 was Citadel Advisors, an estimated $4.16M sold.

Based on aggregated 13F filings for Q2 2017.